File(s) not publicly available
Ecallantide (Dyax/Genzyme)
Ecallantide is one of a series of small-protein kallikrein inhibitors, identified through Dyax Corp's phage display technology, that is being developed by Dyax and Genzyme as a potential subcutaneous treatment for hereditary angioedema (HAE). Dyax is also independently developing ecallantide for the reduction of peri-operative blood loss during cardiopulmonary bypass surgery. The company had expected to begin phase II clinical studies in coronary bypass graft patients in the first half of 2005; however, by October 2005, these trials had been delayed until partnership negotiations for the program were completed. A pivotal, phase III clinical trial of ecallantide in HAE began in December 2005.
History
Publication status
- Published
Journal
Current Opinion in Investigational DrugsISSN
1472-4472Publisher
Thomson ReutersIssue
3Volume
7Page range
282-90Notes
GDSC201Full text available
- No
Peer reviewed?
- No